Patient outcomes and long-term toxicity (A) response and survival, (B) long-term toxicity
| (A) Best response | Metastatic melanoma | Metastatic renal cell |
| (n=54) | (n=46) | |
| CR | 43 | 38 |
| Surgical/SRS CRs | 9 | 5 |
| PR No further treatment | 2 | 3 |
| Median follow-up | 10+ years | 10.5+ years |
| Range follow-up | 5+ to 15+ years | 5+ to 30+ years |
| Alive >10 years after IL-2 with no subsequent therapy | 32 patients | 27 patients |
| (B) Event | # Patients |
| Hypothyroidism—requiring replacement medication (grade 2) | 5 |
| Arthralgias/Arthritis (grade 1–2) | 6 |
| Vitiligo (grade 1–2) | 3 |
| Neuropathy (grade 2) | 1 |
| Premature ventricular contractions (grade 1) | 1 |
| Normal pressure hydrocephalus (grade 1) | 1 |
CR, complete response; DFS, disease-free survival; IL-2, interleukin-2; PR, partial response; SRS, stereotactic radiosurgery.